Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases
  • 18
    May

Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases

Illkirch Graffenstaden, France – May 18, 2017 – Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases. BI-ANAG PR May 18 2017 BI - Anagenesis CP_18 mai 2017

Read More
Job Offer
  • 27
    Oct

Job Offer

scientist-position

Read More
Anagenesis Biotechnologies reinforces its Scientific Team
  • 6
    Sep

Anagenesis Biotechnologies reinforces its Scientific Team

Anagenesis announces Professor Helen Blau, joining the scientific team to develop novel therapies for Muscles Diseases. H-Blau_Anagenesis PR_090616

Read More
Nature Protocols publication
  • 2
    Sep

Nature Protocols publication

Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro ChalAlTanouryetal_nprot.2016.110

Read More
CRISPR Therapeutics and Anagenesis Biotechnologies announce Strategic In-Licensing and Collaboration Agreement.
  • 8
    Jun

CRISPR Therapeutics and Anagenesis Biotechnologies announce Strategic In-Licensing and Collaboration Agreement.

CRISPR Therapeutics and Anagenesis Biotechnologies announce Strategic In-Licensing and Collaboration Agreement to develop CRISPR/Cas9-Based Cell Therapies for Muscles Diseases. Crispr_Anagenesis PR_6 8 16 CRISPR - Anagenesis CP_FR 8 06 16 F

Read More
Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston
  • 19
    Apr

Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston

Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston, Massachusetts to carry out its cell therapy programs. PR AnaG Biotherapies EN CP AnaG Biotherapies FR Anagenesis Biotherapies - MLSC PR 04-19-2016

Read More
Anagenesis Biotechnologies and Ksilink, a one-of-a-kind collaboration
  • 4
    Feb

Anagenesis Biotechnologies and Ksilink, a one-of-a-kind collaboration

Anagenesis Biotechnologies and Ksilink announce a collaborative research agreement to develop new small molecule therapies against DMD. PR collab Anagenesis-KSILINK_VF_EN PR collab Anagenesis-KSILINK_VF_FR

Read More
Anagenesis Biotechnologies member of Bpifrance Excellence
  • 27
    Aug

Anagenesis Biotechnologies member of Bpifrance Excellence

Anagenesis Biotechnologies has been elected member of Bpifrance Excellence. http://www.excellence.bpifrance.fr/

Read More
Anagenesis Biotechnologies' technology rewarded by the international scientific community through publication in Nature Biotechnology
  • 5
    Aug

Anagenesis Biotechnologies’ technology rewarded by the international scientific community through publication in Nature Biotechnology

Anagenesis Biotechnologies announced today a key publication in Nature Biotechnology. The article is entitled “Differentiating embryonic stem cells to muscle fibers to model Duchenne Muscular Dystrophy” by Jérôme Chal et al. from the lab of Pr Olivier Pourquié (the two scientists inventors of Anagenesis Biotechnologies technology) together with co-authors from Anagenesis Biotechnologies. Lean more in our press release:...

Read More
BioPharm America 2015
  • 30
    Jul

BioPharm America 2015

Anagenesis Biotechnologies has been selected to present at Biopharm America 2015. The Event will be held from September 15th to September 17th, 2015.  BioPharm America - Bing www.ebdgroup.com/bpa/program

Read More